Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Injections, Intravenous"" wg kryterium: Temat


Tytuł :
Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure.
Autorzy :
Fudim M; Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Duke University Medical Center, Durham, NC. Electronic address: .
Spates T; Division of Cardiology, Duke University Medical Center, Durham, NC.
Sun JL; Duke Clinical Research Institute, Durham, NC.
Kittipibul V; Department of Medicine, University of Miami, Miami, Fl.
Testani JM; Division of Cardiology, Yale, New Haven.
Starling RC; Division of Cardiology, Cleveland Clinic, Cleveland, OH.
Tang WHW; Division of Cardiology, Cleveland Clinic, Cleveland, OH.
Hernandez AF; Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Duke University Medical Center, Durham, NC.
Felker GM; Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Duke University Medical Center, Durham, NC.
O'Connor CM; Inova Heart and Vascular Institute, Falls Church, VA.
Mentz RJ; Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Duke University Medical Center, Durham, NC.
Pokaż więcej
Źródło :
American heart journal [Am Heart J] 2021 Sep; Vol. 239, pp. 110-119. Date of Electronic Publication: 2021 May 27.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Furosemide*/administration & dosage
Furosemide*/adverse effects
Heart Failure*/blood
Heart Failure*/drug therapy
Heart Failure*/mortality
Heart Failure*/physiopathology
Infusions, Intravenous*/adverse effects
Infusions, Intravenous*/methods
Injections, Intravenous*/adverse effects
Injections, Intravenous*/methods
Creatinine/blood ; Diuretics/administration & dosage ; Diuretics/adverse effects ; Drug Monitoring/methods ; Female ; Hospitalization/statistics & numerical data ; Humans ; Male ; Middle Aged ; Mortality ; Natriuretic Peptide, Brain/blood ; Outcome and Process Assessment, Health Care ; Patient Readmission/statistics & numerical data ; Peptide Fragments/blood ; Time-to-Treatment ; United States/epidemiology
Czasopismo naukowe
Tytuł :
Intraoperative Identification of the Shunt Point of Spinal Arteriovenous Malformations by a Selective Arterial Injection of Saline to Subtract Signals of Indocyanine Green: Technical Note.
Autorzy :
Takamiya S; Department of Neurosurgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Electronic address: .
Yamazaki K; Department of Neurosurgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Tokairin K; Department of Neurosurgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Osanai T; Department of Neurosurgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Shindo T; Department of Neurosurgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Seki T; Department of Neurosurgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Fujimura M; Department of Neurosurgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Pokaż więcej
Źródło :
World neurosurgery [World Neurosurg] 2021 Jul; Vol. 151, pp. 132-137. Date of Electronic Publication: 2021 May 15.
Typ publikacji :
Journal Article
MeSH Terms :
Injections, Intravenous*/methods
Arteriovenous Malformations/*surgery
Coloring Agents/*therapeutic use
Indocyanine Green/*therapeutic use
Angiography, Digital Subtraction/methods ; Arteriovenous Fistula/surgery ; Coloring Agents/administration & dosage ; Humans ; Indocyanine Green/administration & dosage ; Saline Solution
Czasopismo naukowe
Tytuł :
Effect of Intravenous Lidocaine on Inflammatory and Apoptotic Response of Ischemia-Reperfusion Injury in Pigs Undergoing Lung Resection Surgery.
Autorzy :
Romera A; Department of Anesthesiology, Gregorio Marañón University Hospital, Madrid, Spain.
Cebollero M; Department of Anatomic Pathology, Gregorio Marañón University Hospital, Madrid, Spain.
Romero-Gómez B; Department of Immunology, Ophthalmology and Otorhinolaryngology, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
Carricondo F; Department of Immunology, Ophthalmology and Otorhinolaryngology, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
Zapatero S; Department of Anesthesiology, Gregorio Marañón University Hospital, Madrid, Spain.
García-Aldao U; Department of Anesthesiology, Gregorio Marañón University Hospital, Madrid, Spain.
Martín-Albo L; Department of Thoracic Surgery, Gregorio Marañón University Hospital, Madrid, Spain.
Ortega J; Department of Thoracic Surgery, Gregorio Marañón University Hospital, Madrid, Spain.
Vara E; Department of Biochemistry and Molecular Biology III, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
Garutti I; Department of Anesthesiology, Gregorio Marañón University Hospital, Madrid, Spain.
Simón C; Department of Thoracic Surgery, Gregorio Marañón University Hospital, Madrid, Spain.
Pokaż więcej
Źródło :
BioMed research international [Biomed Res Int] 2021 Jun 04; Vol. 2021, pp. 6630232. Date of Electronic Publication: 2021 Jun 04 (Print Publication: 2021).
Typ publikacji :
Journal Article
MeSH Terms :
Injections, Intravenous*
Apoptosis/*drug effects
Inflammation/*drug therapy
Lidocaine/*administration & dosage
Lung/*surgery
Reperfusion Injury/*drug therapy
Animals ; Anti-Inflammatory Agents/administration & dosage ; Antigens, CD/metabolism ; Antigens, Differentiation, Myelomonocytic/metabolism ; Biopsy ; Caspase 9/metabolism ; Chemokine CCL2/metabolism ; Hemodynamics ; Lung/drug effects ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Swine
Czasopismo naukowe
Tytuł :
The effects of ceftriaxone by intravenous push on adverse drug reactions in the emergency department.
Autorzy :
Agunbiade A; Cook County Health, 1950 W Polk St, 7th Floor, Chicago, IL 60612, United States of America. Electronic address: .
Routsolias JC; Cook County Health, 1950 W Polk St, 7th Floor, Chicago, IL 60612, United States of America.
Rizvanolli L; Cook County Health, 1950 W Polk St, 7th Floor, Chicago, IL 60612, United States of America.
Bleifuss W; Cook County Health, 1950 W Polk St, 7th Floor, Chicago, IL 60612, United States of America.
Sundaresan S; Cook County Health, 1950 W Polk St, 7th Floor, Chicago, IL 60612, United States of America.
Moskoff J; Cook County Health, 1950 W Polk St, 7th Floor, Chicago, IL 60612, United States of America.
Pokaż więcej
Źródło :
The American journal of emergency medicine [Am J Emerg Med] 2021 May; Vol. 43, pp. 245-248. Date of Electronic Publication: 2020 Mar 30.
Typ publikacji :
Journal Article
MeSH Terms :
Anti-Bacterial Agents/*administration & dosage
Ceftriaxone/*administration & dosage
Injections, Intravenous/*adverse effects
Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/adverse effects ; Ceftriaxone/adverse effects ; Emergency Service, Hospital/statistics & numerical data ; Female ; Humans ; Injections, Intravenous/economics ; Male ; Middle Aged ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Assembly and operation of an easy-to-make portable device for facilitating mouse lateral tail-vein injection.
Autorzy :
Wu Q; Department of Orthopaedics, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Xing Z; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.
Luo S; State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.
Chen B; Department of Orthopaedics, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Yu X; Department of Orthopaedics, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Tao R; Department of Orthopaedics, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Bao N; Department of Orthopaedics, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China. .
Zhao J; Department of Orthopaedics, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China. .
Pokaż więcej
Źródło :
Lab animal [Lab Anim (NY)] 2022 Jan; Vol. 51 (1), pp. 11-21. Date of Electronic Publication: 2021 Dec 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Tail*
Animals ; Injections, Intravenous ; Mice
Czasopismo naukowe
Tytuł :
The pharmacokinetic characteristics of sulfadiazine in channel catfish (Ictalurus punctatus) following oral and intravenous administrations.
Autorzy :
Xu N; Yangtze River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Wuhan, China.; Hu Bei Province Engineering and Technology Research Center of Aquatic Product Quality and Safety, Wuhan, China.
Fu Y; Hunan University of Arts and Science, Changde, China.
Zhang X; Hunan Applied Technology University, Changde, China.
Liu Y; Yangtze River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Wuhan, China.; Hu Bei Province Engineering and Technology Research Center of Aquatic Product Quality and Safety, Wuhan, China.; Key Laboratory of Control of Quality and Safety for Aquatic Products, Ministry of Agriculture, Beijing, China.
Yang Y; Yangtze River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Wuhan, China.; Hu Bei Province Engineering and Technology Research Center of Aquatic Product Quality and Safety, Wuhan, China.
Zhou S; Yangtze River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Wuhan, China.; Hu Bei Province Engineering and Technology Research Center of Aquatic Product Quality and Safety, Wuhan, China.
Dong J; Yangtze River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Wuhan, China.; Hu Bei Province Engineering and Technology Research Center of Aquatic Product Quality and Safety, Wuhan, China.
Yang Q; Yangtze River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Wuhan, China.; Hu Bei Province Engineering and Technology Research Center of Aquatic Product Quality and Safety, Wuhan, China.
Ai X; Yangtze River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Wuhan, China.; Hu Bei Province Engineering and Technology Research Center of Aquatic Product Quality and Safety, Wuhan, China.; Key Laboratory of Control of Quality and Safety for Aquatic Products, Ministry of Agriculture, Beijing, China.
Pokaż więcej
Źródło :
Journal of veterinary pharmacology and therapeutics [J Vet Pharmacol Ther] 2022 Jan; Vol. 45 (1), pp. 16-22. Date of Electronic Publication: 2021 Nov 15.
Typ publikacji :
Journal Article
MeSH Terms :
Ictaluridae*
Sulfadiazine*
Administration, Intravenous/veterinary ; Administration, Oral ; Animals ; Area Under Curve ; Biological Availability ; Half-Life ; Injections, Intravenous/veterinary
Czasopismo naukowe
Tytuł :
Intravenous injection of mesenchymal stem cell spheroids improves the pulmonary delivery and prolongs in vivo survival.
Autorzy :
Shimazawa Y; Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan.
Kusamori K; Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan.
Tsujimura M; Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan.
Shimomura A; Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan.
Takasaki R; Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan.
Takayama Y; Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan.
Shimizu K; Department of Biomolecular Engineering, Graduate School of Engineering, Nagoya University, Nagoya, Aichi, Japan.
Konishi S; Department of Mechanical Engineering, Graduate School of Science and Engineering, Ritsumeikan University, Kusatsu, Shiga, Japan.
Nishikawa M; Laboratory of Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, Japan.
Pokaż więcej
Źródło :
Biotechnology journal [Biotechnol J] 2022 Jan; Vol. 17 (1), pp. e2100137. Date of Electronic Publication: 2021 Oct 08.
Typ publikacji :
Journal Article
MeSH Terms :
Mesenchymal Stem Cell Transplantation*
Mesenchymal Stem Cells*
Adipose Tissue ; Animals ; Injections, Intravenous ; Lung ; Mice ; Spheroids, Cellular
Czasopismo naukowe
Tytuł :
Characterization and Cost of Intravenous Drug Use-Associated Upper Extremity Infections Requiring Operative Treatment.
Autorzy :
Katabi LJ; Case Western Reserve University School of Medicine.
Ascha M; Division of Plastic Surgery, Department of Surgery, University Hospitals Cleveland Medical Center.
Wu-Fienberg Y; Division of Plastic Surgery, Department of Surgery, University Hospitals Cleveland Medical Center.
Todd Bafus B; Department of Orthopedic Surgery, Metrohealth Medical Center.
Chepla KJ; Division of Plastic Surgery, Department of Surgery, Metrohealth Medical Center, Cleveland, Ohio.
Pokaż więcej
Źródło :
Plastic and reconstructive surgery [Plast Reconstr Surg] 2022 Jan 01; Vol. 149 (1), pp. 155e-156e.
Typ publikacji :
Journal Article
MeSH Terms :
Cost of Illness*
Hospital Costs/*statistics & numerical data
Soft Tissue Infections/*economics
Substance Abuse, Intravenous/*complications
Upper Extremity/*surgery
Adult ; Humans ; Injections, Intravenous/adverse effects ; Length of Stay/economics ; Length of Stay/statistics & numerical data ; Middle Aged ; Retrospective Studies ; Soft Tissue Infections/epidemiology ; Soft Tissue Infections/etiology ; Soft Tissue Infections/surgery ; United States/epidemiology
Czasopismo naukowe
Tytuł :
Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: Liraglutide, insulin aspart and insulin detemir.
Autorzy :
Pedersen KM; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv.
Gradel AKJ; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv; Department of Veterinary and Animal Sciences, Section for Experimental Animal Models, University of Copenhagen. Electronic address: .
Ludvigsen TP; Translational Medicine, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv.
Christoffersen BØ; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv.
Fuglsang-Damgaard CA; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv.
Bendtsen KM; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv.
Madsen SH; Translational Medicine, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv.
Manfé V; Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv.
Refsgaard HHF; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv.
Pokaż więcej
Źródło :
Translational research : the journal of laboratory and clinical medicine [Transl Res] 2022 Jan; Vol. 239, pp. 71-84. Date of Electronic Publication: 2021 Aug 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Insulin Aspart/*pharmacokinetics
Insulin Detemir/*pharmacokinetics
Liraglutide/*pharmacokinetics
Animals ; Humans ; Injections, Intravenous ; Injections, Subcutaneous ; Insulin Aspart/administration & dosage ; Insulin Detemir/administration & dosage ; Liraglutide/administration & dosage ; Sus scrofa ; Swine ; Swine, Miniature ; Translational Research, Biomedical
Czasopismo naukowe
Tytuł :
Analgesic Effects of Different κ -Receptor Agonists Used in Daytime Laparoscopic Cholecystectomy.
Autorzy :
Zhou W; Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Wang J; Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Hu C; Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Dai F; Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Zhang Z; Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230036, China.
Li C; Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Tang C; Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Xie Y; Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
Pokaż więcej
Źródło :
BioMed research international [Biomed Res Int] 2021 Dec 29; Vol. 2021, pp. 2396008. Date of Electronic Publication: 2021 Dec 29 (Print Publication: 2021).
Typ publikacji :
Journal Article
MeSH Terms :
Analgesics, Opioid/*therapeutic use
Cholecystectomy, Laparoscopic/*adverse effects
Pain, Postoperative/*drug therapy
Receptors, Opioid, kappa/*agonists
Analgesia/methods ; Female ; Humans ; Injections, Intravenous/methods ; Male ; Middle Aged ; Morphine/therapeutic use ; Nalbuphine/therapeutic use ; Oxycodone/therapeutic use ; Pain Management/methods ; Pain Measurement/methods
Czasopismo naukowe
Tytuł :
Trial of Spesolimab for Generalized Pustular Psoriasis.
Autorzy :
Bachelez H; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Choon SE; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Marrakchi S; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Burden AD; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Tsai TF; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Morita A; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Navarini AA; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Zheng M; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Xu J; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Turki H; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Anadkat MJ; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Rajeswari S; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Hua H; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Vulcu SD; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Hall D; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Tetzlaff K; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Thoma C; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Lebwohl MG; From Service de Dermatologie, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université de Paris - both in Paris (H.B.); the Department of Dermatology, Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Monash University Malaysia, Subang Jaya, Malaysia (S.-E.C.); the Dermatology Department, Hedi Chaker University Hospital, Sfax, Tunisia (S.M., H.T.); the Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom (A.D.B.); the Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (T.-F.T.); the Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Japan (A.M.); the Department of Dermatology, University Hospital Basel, Basel, Switzerland (A.A.N.); the Department of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou (M.Z.), and the Department of Dermatology, Huashan Hospital, Fudan University (J.X.), and Boehringer Ingelheim (China) Investment Company (H.H.), Shanghai - all in China; Washington University School of Medicine, Division of Dermatology, St. Louis (M.J.A.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.R., D.H.); Boehringer Ingelheim International, Ingelheim (S.D.V., K.T.), the Medical Clinic, Department of Sports Medicine, University of Tuebingen, Tuebingen (K.T.), and Boehringer Ingelheim International, Biberach (C.T.) - all in Germany; and the Icahn School of Medicine at Mount Sinai, New York (M.G.L.).
Pokaż więcej
Corporate Authors :
Effisayil 1 Trial Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Dec 23; Vol. 385 (26), pp. 2431-2440.
Typ publikacji :
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Psoriasis/*drug therapy
Receptors, Interleukin/*antagonists & inhibitors
Adult ; Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Double-Blind Method ; Female ; Humans ; Injections, Intravenous ; Male ; Middle Aged ; Placebos/adverse effects ; Placebos/therapeutic use ; Severity of Illness Index ; Symptom Flare Up
Czasopismo naukowe
Tytuł :
Slower vs Faster Intravenous Fluid Bolus Rates and Mortality in Critically Ill Patients.
Autorzy :
Chapalain X; Department of Anesthesiology and Intensive Care Medicine, Brest University Hospital, Brest, France.
Huet O; Department of Anesthesiology and Intensive Care Medicine, Brest University Hospital, Brest, France.
Pokaż więcej
Źródło :
JAMA [JAMA] 2021 Dec 14; Vol. 326 (22), pp. 2331-2332.
Typ publikacji :
Letter; Comment
MeSH Terms :
Critical Illness*
Fluid Therapy*
Humans ; Injections, Intravenous
Opinia redakcyjna
Tytuł :
Slower vs Faster Intravenous Fluid Bolus Rates and Mortality in Critically Ill Patients-Reply.
Autorzy :
Zampieri FG; HCor Research Institute, Brazil Research in Intensive Care Medicine Network-BRICNet, São Paulo, Brazil.
Cavalcanti AB; HCor Research Institute, Brazil Research in Intensive Care Medicine Network-BRICNet, São Paulo, Brazil.
Pokaż więcej
Źródło :
JAMA [JAMA] 2021 Dec 14; Vol. 326 (22), pp. 2332.
Typ publikacji :
Letter; Comment
MeSH Terms :
Critical Illness*
Fluid Therapy*
Humans ; Injections, Intravenous
Opinia redakcyjna
Tytuł :
Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Autorzy :
Li Q; College of Chemistry and Materials Science, Sichuan Normal University, Chengdu, 610068, China. Electronic address: .
Deng X; Pharmaceutical College, Guangxi Medical University, Nanning, 530021, China.
Jiang N; Department of Pharmacy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530021, China.
Meng L; Pharmaceutical College, Guangxi Medical University, Nanning, 530021, China.
Xing J; Department of Organic Chemistry and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Jiang W; Pharmaceutical College, Guangxi Medical University, Nanning, 530021, China.
Xu Y; College of Chemistry and Materials Science, Sichuan Normal University, Chengdu, 610068, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Dec 05; Vol. 225, pp. 113765. Date of Electronic Publication: 2021 Aug 10.
Typ publikacji :
Journal Article
MeSH Terms :
Diabetes Mellitus, Experimental/*drug therapy
Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl Peptidase 4/*metabolism
Dipeptidyl-Peptidase IV Inhibitors/*pharmacology
Hypoglycemic Agents/*pharmacology
Administration, Oral ; Animals ; Benzoic Acid/administration & dosage ; Benzoic Acid/blood ; Benzoic Acid/pharmacology ; Cell Line ; Cell Survival/drug effects ; Diabetes Mellitus, Experimental/blood ; Diabetes Mellitus, Experimental/metabolism ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/metabolism ; Dipeptidyl-Peptidase IV Inhibitors/administration & dosage ; Dipeptidyl-Peptidase IV Inhibitors/blood ; Dose-Response Relationship, Drug ; Esters/administration & dosage ; Esters/blood ; Esters/pharmacology ; Humans ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/blood ; Injections, Intravenous ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Inbred ICR ; Models, Molecular ; Molecular Structure ; Rats ; Rats, Sprague-Dawley ; Structure-Activity Relationship ; Uracil/administration & dosage ; Uracil/blood ; Uracil/pharmacology
Czasopismo naukowe
Tytuł :
Therapeutic Effect of IL-38 on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Cell Pathogenicity.
Autorzy :
Li H; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Zhu L; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Wang R; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Xie L; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Chen Y; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Duan R; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Liu X; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Huang Z; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Chen B; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Li Z; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Wang X; Eye Center of Xiangya Hospital, Central South University, Changsha, China.; Hunan Key Laboratory of Ophthalmology, Xiangya Hospital, Central South University, Changsha, China.
Su W; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Pokaż więcej
Źródło :
Investigative ophthalmology & visual science [Invest Ophthalmol Vis Sci] 2021 Dec 01; Vol. 62 (15), pp. 31.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Autoimmune Diseases/*drug therapy
Immune System/*physiology
Interleukins/*therapeutic use
Th17 Cells/*immunology
Uveitis/*drug therapy
Adoptive Transfer ; Animals ; Antigen-Presenting Cells/immunology ; Autoimmune Diseases/chemically induced ; Autoimmune Diseases/immunology ; B-Lymphocytes/immunology ; Coculture Techniques ; Disease Models, Animal ; Enzyme-Linked Immunosorbent Assay ; Female ; Flow Cytometry ; Granulocyte-Macrophage Colony-Stimulating Factor/metabolism ; Injections, Intravenous ; Interleukin-23/metabolism ; Lymph Nodes/immunology ; Mice ; Mice, Inbred C57BL ; Neck ; Recombinant Proteins/therapeutic use ; Retina/immunology ; Sequence Analysis, RNA ; Single-Cell Analysis ; T-Lymphocytes/immunology ; Th1 Cells/immunology ; Uveitis/chemically induced ; Uveitis/immunology
Czasopismo naukowe
Tytuł :
Evaluation of transgene expression characteristics and DNA vaccination against melanoma metastasis of an intravenously injected ternary complex with biodegradable dendrigraft poly-L-lysine in mice.
Autorzy :
Kodama Y; Department of Hospital Pharmacy, Nagasaki University Hospital, Nagasaki, Japan.
Tokunaga A; Department of Hospital Pharmacy, Nagasaki University Hospital, Nagasaki, Japan.
Hashizume J; Department of Hospital Pharmacy, Nagasaki University Hospital, Nagasaki, Japan.
Nakagawa H; Department of Hospital Pharmacy, Nagasaki University Hospital, Nagasaki, Japan.
Harasawa H; Department of Hospital Pharmacy, Nagasaki University Hospital, Nagasaki, Japan.
Kurosaki T; Department of Hospital Pharmacy, Nagasaki University Hospital, Nagasaki, Japan.
Nakamura T; Department of Hospital Pharmacy, Nagasaki University Hospital, Nagasaki, Japan.; Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Nishida K; Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Nakashima M; Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Hashida M; Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Kawakami S; Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Sasaki H; Department of Hospital Pharmacy, Nagasaki University Hospital, Nagasaki, Japan.
Pokaż więcej
Źródło :
Drug delivery [Drug Deliv] 2021 Dec; Vol. 28 (1), pp. 542-549.
Typ publikacji :
Journal Article
MeSH Terms :
Cancer Vaccines/*administration & dosage
Melanoma, Experimental/*therapy
Transgenes/*genetics
Vaccines, DNA/*administration & dosage
Animals ; Cancer Vaccines/toxicity ; Clodronic Acid/administration & dosage ; Clodronic Acid/pharmacology ; Injections, Intravenous ; Liposomes ; Liver/metabolism ; Macrophages/metabolism ; Male ; Melanoma, Experimental/genetics ; Mice ; Mice, Inbred C57BL ; Plasmids/genetics ; Polyglutamic Acid/analogs & derivatives ; Polyglutamic Acid/chemistry ; Polylysine/chemistry ; RAW 264.7 Cells ; Spleen/metabolism ; Transfection ; Vaccines, DNA/toxicity
Czasopismo naukowe
Tytuł :
Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.
Autorzy :
Stevens SM; Department of Medicine, Intermountain Healthcare, Murray, UT.
Woller SC; Department of Medicine, Intermountain Healthcare, Murray, UT. Electronic address: .
Baumann Kreuziger L; Versiti Blood Research Institute and Medical College of Wisconsin, Milwaukee, WI.
Bounameaux H; Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Doerschug K; Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA.
Geersing GJ; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Huisman MV; Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.
Kearon C; McMaster University, Hamilton, ON, Canada.
King CS; Advanced Lung Disease and Transplant Clinic, Inova Fairfax Hospital, Falls Church, VA.
Knighton AJ; Healthcare Delivery Institute, Intermountain Healthcare, Murray, UT.
Lake E; Essentia Institute of Rural Health, Duluth, MN.
Murin S; University of California Davis School of Medicine, Davis, CA.
Vintch JRE; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA.
Wells PS; Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Moores LK; Department of Medicine, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD.
Pokaż więcej
Źródło :
Chest [Chest] 2021 Dec; Vol. 160 (6), pp. 2247-2259. Date of Electronic Publication: 2021 Aug 02.
Typ publikacji :
Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
MeSH Terms :
Fibrinolytic Agents/*therapeutic use
Pulmonary Embolism/*drug therapy
Thrombolytic Therapy/*methods
Venous Thrombosis/*drug therapy
Drug Therapy, Combination ; Evidence-Based Medicine ; Fondaparinux/therapeutic use ; Heparin, Low-Molecular-Weight/therapeutic use ; Humans ; Injections, Intravenous ; Injections, Subcutaneous ; International Normalized Ratio ; Risk Assessment ; Vitamin K/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Antibiotic Use in Term and Near-Term Newborns.
Autorzy :
Mundal HS; Paediatric Department, Ostfold Hospital Trust, Grålum, Norway.
Rønnestad A; NICU, Clinic of Pediatric and Adolescent Medicine.; Neonatal Clinical and Epidemiological Research Group, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine.
Klingenberg C; Paediatric Research Group, Faculty of Health Sciences, University of Tromsø-The Arctic University of Norway, Tromsø, Norway.; Department of Paediatrics, University Hospital of North Norway, Tromsø, Norway.
Stensvold HJ; NICU, Clinic of Pediatric and Adolescent Medicine.; Neonatal Clinical and Epidemiological Research Group, Oslo University Hospital, Oslo, Norway.
Størdal K; NICU, Clinic of Pediatric and Adolescent Medicine.; Pediatric Research Institute, Faculty of Medicine, University of Oslo, Oslo, Norway.
Pokaż więcej
Źródło :
Pediatrics [Pediatrics] 2021 Dec 01; Vol. 148 (6).
Typ publikacji :
Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Antimicrobial Stewardship*
Gestational Age*
Term Birth*
Anti-Bacterial Agents/*administration & dosage
Sepsis/*drug therapy
Anti-Bacterial Agents/adverse effects ; Bacterial Infections/drug therapy ; Bacterial Infections/epidemiology ; Bacterial Infections/microbiology ; Blood Culture ; Drug Administration Schedule ; Humans ; Infant, Newborn ; Infant, Premature ; Injections, Intravenous/statistics & numerical data ; Norway/epidemiology ; Sepsis/diagnosis ; Sepsis/epidemiology ; Sepsis/microbiology
Czasopismo naukowe
Tytuł :
Antitumor efficacy of CHMFL-KIT-110 solid dispersion in mouse xenograft models of human gastrointestinal stromal tumors.
Autorzy :
Wang S; Institute of Clinical Pharmacology, Anhui Medical University, 81 Meishan Road, Hefei, 230032, China.; Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education; Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, 81 Meishan Road, Hefei, 230032, China.
Wang C; Hefei Blooming Drug Safety Evaluation Co., Ltd, 358 Ganquan Road, Hefei, 230031, China.; Anhui Province Key Laboratory of Druggability Evaluation for New Drugs, 358 Ganquan Road, Hefei, 230031, China.
Wang X; Hefei Blooming Drug Safety Evaluation Co., Ltd, 358 Ganquan Road, Hefei, 230031, China.; Anhui Province Key Laboratory of Druggability Evaluation for New Drugs, 358 Ganquan Road, Hefei, 230031, China.
Wang X; Institute of Clinical Pharmacology, Anhui Medical University, 81 Meishan Road, Hefei, 230032, China.; Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education; Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, 81 Meishan Road, Hefei, 230032, China.
Huang L; Institute of Clinical Pharmacology, Anhui Medical University, 81 Meishan Road, Hefei, 230032, China.; Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education; Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, 81 Meishan Road, Hefei, 230032, China.
Kuai J; Institute of Clinical Pharmacology, Anhui Medical University, 81 Meishan Road, Hefei, 230032, China.; Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education; Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, 81 Meishan Road, Hefei, 230032, China.
Wei W; Institute of Clinical Pharmacology, Anhui Medical University, 81 Meishan Road, Hefei, 230032, China.; Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education; Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, 81 Meishan Road, Hefei, 230032, China.
Lu X; Hefei Blooming Drug Safety Evaluation Co., Ltd, 358 Ganquan Road, Hefei, 230031, China. .; Anhui Province Key Laboratory of Druggability Evaluation for New Drugs, 358 Ganquan Road, Hefei, 230031, China. .
Yan S; Institute of Clinical Pharmacology, Anhui Medical University, 81 Meishan Road, Hefei, 230032, China. .; Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education; Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, 81 Meishan Road, Hefei, 230032, China. .
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 Nov; Vol. 88 (5), pp. 795-804. Date of Electronic Publication: 2021 Jul 26.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Benzamides/*pharmacology
Gastrointestinal Neoplasms/*drug therapy
Gastrointestinal Stromal Tumors/*drug therapy
Isonicotinic Acids/*pharmacology
Administration, Oral ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacokinetics ; Benzamides/administration & dosage ; Benzamides/pharmacokinetics ; Cell Line, Tumor ; Gastrointestinal Neoplasms/pathology ; Gastrointestinal Stromal Tumors/pathology ; Humans ; Injections, Intravenous ; Isonicotinic Acids/administration & dosage ; Isonicotinic Acids/pharmacokinetics ; Male ; Mice ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/pharmacology ; Proto-Oncogene Proteins c-kit/antagonists & inhibitors ; Proto-Oncogene Proteins c-kit/blood ; Xenograft Model Antitumor Assays
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies